AVENTURA, Fla. and NATICK,
Mass., May 6, 2022
/PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia
Therapeutics"), a global biotechnology company focused on
harnessing the power of natural killer (NK) cells to fight cancer
through multispecific antibodies and stem cell engineering,
announced today that it will be presenting at the AACR Special
Conference on Advances in the Pathogenesis and Molecular Therapies
of Liver Cancer, to be held from May 5-8,
2022, at the Westin Copley Place in Boston, Massachusetts. The conference is an
in-person event and will not live-stream content, but Cytovia
Therapeutics's short poster video will be available for on-demand
viewing by conference registrants after the conference and Cytovia
Therapeutics's poster will be available on its website under the
"Resources" section.
Details of Cytovia's poster presentation:
Abstract
title: Preclinical activity of glypican-3 (GPC3) and NKp46
directed FLEX-NK™ engager antibody (CYT-303) in combination with
iPSC derived natural killer cells (iNKs) or peripheral blood (PB)
NK cells in hepatocellular carcinoma (HCC)
Session: Poster Session/Reception
Session Date and Start Time: Friday, May 6, 5:30-7:30 p.m.
Conclusions from the poster:
- The FLEX-NKTM multifunctional engager antibody
CYT-303 directed against NKp46 and GPC3 demonstrated potent single
agent anti-tumor activity:
-
- potent NK cell cytotoxicity against HCC tumor cells accompanied
by cytokine production in an in vitro model indicative
of NK cell engagement and activation
- HCC tumor growth inhibition in an in vivo model
- Favorable cytokine release and immune cell subset safety
profile
- iNK cells expressed a favorable combination of multiple
activation and few inhibitory receptors that facilitated potent
cytolytic activity against HCC tumors
- The combination of the FLEX-NKTM and iNK cells
demonstrated greater in vitro and in vivo anti-tumor
activity in HCC tumor models than iNK cells alone
- The preclinical proof of concept studies with CYT-303 alone or
in combination with iNK cells in HCC warrant clinical
development
About Cytovia Therapeutics
Cytovia Therapeutics is developing novel cell therapies and
immunotherapies aimed at addressing solid and hematological tumors
with significant unmet medical needs. Cytovia Therapeutics focuses
on harnessing the innate immune system by developing complementary
and disruptive NK-cell and NK-engager antibody platforms. The
company is developing three types of iPSC-derived (or iNK) cells:
unedited iNK cells, TALEN® gene-edited iNK cells with improved
function and persistence, and TALEN® gene-edited iNK cells with
chimeric antigen receptors (CAR-iNKs) to improve tumor-specific
targeting. The second complementary cornerstone technology is a
quadrivalent multifunctional antibody platform designed to engage
natural killer cells by targeting NKp46 using Cytovia
Therapeutics's proprietary Flex-NK™ technology.
These two technology platforms are being used to develop
treatments for patients with solid tumors such as HCC and
glioblastoma as well as hematological malignancies such as
refractory multiple myeloma.
Headquartered in Aventura, FL, Cytovia Therapeutics has
research and development laboratories in Natick, MA, and a
cell manufacturing facility in Puerto Rico. The company's own
R&D work is augmented through scientific partnerships with
Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell
Foundation and the University of California San
Francisco (UCSF).
Cytovia Therapeutics has a strategic partnership with CytoLynx
Therapeutics, which is focused on research and development,
manufacturing, and commercialization activities in Greater
China and beyond.
Find out more at www.cytoviatx.com and follow us
on Facebook, Twitter, LinkedIn, YouTube,
and Instagram.
About GPC3
Glypican-3 (GPC3) is a cell-surface heparan sulfate proteoglycan it
is highly expressed in HCC and other pediatric and adult solid
tumors. GPC3 promotes Wnt-dependent cell proliferation, and it has
been strongly suggested that it is related to the malignant
transformation of HCC, making it a promising target for cancer
immunotherapy.
Additional Information and Where to Find It
Isleworth
Healthcare Acquisition Corp. ("Isleworth") (NASDAQ:
ISLE) intends to file a registration statement on Form S-4
with the Securities Exchange Commission (the "SEC"), which will
include a proxy statement/prospectus, that will be both the proxy
statement to be distributed to holders of Isleworth's common stock
in connection with its solicitation of proxies for the vote by
Isleworth's stockholders with respect to the proposed business
combination pursuant to an Merger Agreement and Plan of
Reorganization entered into on April 26,
2022, by and between Isleworth, Cytovia Holdings,
Inc., the parent company of Cytovia Therapeutics ("Cytovia"), IHAC
First Merger Sub Inc., a direct, wholly-owned subsidiary of
Isleworth, IHAC Second Merger Sub LLC, direct, wholly-owned
subsidiary of Isleworth, and Isleworth Healthcare Sponsor I, LLC
(the "Business Combination") and other matters as may be described
in the registration statement, as well as the prospectus relating
to the offer and sale of the securities to be issued in the
business combination. After the registration statement is declared
effective, Isleworth will mail a definitive proxy
statement/prospectus and other relevant documents to its
stockholders. This communication does not contain all the
information that should be considered concerning the Business
Combination and is not intended to form the basis of any investment
decision or any other decision in respect of the business
combination. Isleworth's stockholders and other interested persons
are advised to read, when available, the preliminary proxy
statement/prospectus included in the registration statement and the
amendments thereto and the definitive proxy statement/prospectus
and other documents filed in connection with the Business
Combination, as these materials will contain important information
about Cytovia, Cytovia Therapeutics, Isleworth and the Business
Combination. When available, the definitive proxy
statement/prospectus and other relevant materials for the Business
Combination will be mailed to stockholders of Isleworth as of a
record date to be established for voting on the Business
Combination. Stockholders will also be able to obtain copies of the
preliminary proxy statement, the definitive proxy statement and
other documents filed with the SEC, without charge, once available,
at the SEC's website at www.sec.gov, or by directing a request to
Isleworth's secretary at 360 Central Avenue, First Central Tower,
Suite #800, St. Petersburg,
Florida 33701.
Participants in the Solicitation
Isleworth, Cytovia
and their respective directors, executive officers and other
members of their management and employees, under SEC rules, may be
deemed to be participants in the solicitation of proxies from
Isleworth stockholders in connection with the proposed transaction.
Investors and security holders may obtain more detailed information
regarding the names, affiliations and interests of Isleworth
directors and executive officers in Isleworth's Annual Report on
Form 10-K for the fiscal year ended December
31, 2021, which was filed with the SEC on March 29, 2022. To the extent that holdings of
Isleworth securities have changed since the filing of the Annual
Report on Form 10-K, such changes have been or will be reflected on
Statements of Change in Ownership on Form 4 filed with the SEC.
Information regarding the persons who may, under SEC rules, be
deemed participants in the solicitation of proxies of Isleworth
stockholders in connection with the proposed transaction will be
set forth in the proxy statement/information statement/prospectus
for the proposed transaction when available. Information concerning
the interests of Isleworth participants in the solicitation, which
may, in some cases, be different than those of Isleworth Healthcare
Acquisition Corp.'s equity holders generally, will be set forth in
the proxy statement/information statement/prospectus relating to
the proposed transaction when it becomes available.
Forward Looking Statements
This press release may
contain forward-looking statements, which may be identified by
words such as "aims," "anticipates," "believes," "could,"
"estimates," "expects," "forecasts," "goal," "intends," "may,"
"plans," "possible," "potential," "seeks," "will" and variations of
these words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential of Cytovia's FLEX-NK multifunctional engager antibody
and iNK cells. Cytovia may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including whether the outcome of preclinical studies will be
predictive of clinical trial results. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Cytovia expressly disclaims any obligation to
update any forward-looking statements contained herein, whether
because of any new information, future events, changed
circumstances or otherwise, except as otherwise required by
law.
No Offer or Solicitation
This communication is for
informational purposes only and is neither an offer to purchase,
nor a solicitation of an offer to sell, subscribe for or buy, any
securities or the solicitation of any vote in any jurisdiction
pursuant to the Business Combination or otherwise, nor shall there
be any sale, issuance or transfer or securities in any jurisdiction
in contravention of applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytovia-therapeutics-to-present-at-aacr-special-conference-on-advances-in-the-pathogenesis-and-molecular-therapies-of-liver-cancer-301542038.html
SOURCE Cytovia Therapeutics
